Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Hsiu‐Mei Chang"'
Publikováno v:
Respirology Case Reports, Vol 11, Iss 3, Pp n/a-n/a (2023)
Abstract Coronavirus disease‐2019 (COVID‐19) is a highly spread infectious disease around the world. This infectious disease impacts whole body systems, specifically on respiratory system. This 57‐year‐old women had diagnosed COVID‐19 posit
Externí odkaz:
https://doaj.org/article/efda95bd44aa4e248ce4cb80332ce3ba
Autor:
Wen-Han Feng, Yong-Chieh Chang, Yi-Hsiung Lin, Hsiao-Ling Chen, Chun-Yin Chen, Tsung-Han Lin, Tzu-Chieh Lin, Ching-Tang Chang, Hsuan-Fu Kuo, Hsiu-Mei Chang, Chih-Sheng Chu
Publikováno v:
Pharmaceuticals, Vol 16, Iss 2, p 232 (2023)
P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it could lower the risk of bleeding complications without increased ischemi
Externí odkaz:
https://doaj.org/article/20e4e9e5d2fc40fb958f0683dc6780d1
Autor:
Wen-Han Feng, Yong-Chieh Chang, Yi-Hsiung Lin, Hsiao-Ling Chen, Hsiu-Mei Chang, Chih-Sheng Chu
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 9, p 4549 (2022)
Increasing evidence has shown P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) with stent implantation in the modern era. However, patients with diabetes mellitus (DM) have a
Externí odkaz:
https://doaj.org/article/611c40c736c5455ab6f6298dd0380913
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 36, Iss 8, Pp 661-662 (2020)
Externí odkaz:
https://doaj.org/article/11b8900ea1f44d51a344fc6f9ba1661f
Publikováno v:
Respirology Case Reports. 11
Autor:
Yu-Chen Tsai, Hsiao-Ling Chen, Tai-Huang Lee, Hsiu-Mei Chang, Kuan-Li Wu, Cheng-Hao Chuang, Yong-Chieh Chang, Yu-Kang Tu, Jen-Yu Hung, Chih-Jen Yang, Inn-Wen Chong
Publikováno v:
Cancers, Vol 14, Iss 182, p 182 (2022)
Cancers
Cancers
Simple Summary Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options. Pemetrexed plus platinum is a standard first-line therapy, but options for second-line therapy in patients with relapsed mesothelioma remain
Autor:
Tai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, Chiou-Mei Wu, Kuan-Li Wu, Chia-Yu Kuo, Po-Ju Wei, Chin-Ling Chen, Hui-Lin Liu, Jen-Yu Hung, Chih-Jen Yang, Inn-Wen Chong
Publikováno v:
Journal of clinical medicine. 11(12)
Patients with advanced non-small cell lung cancer (NSCLC) who harbor susceptible epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine kinase inhibitors (TKIs) show longer progression-free survival (PFS) than those trea
Autor:
Chih-Jen Yang, Tai-Huang Lee, Hsiao-Ling Chen, Jen-Yu Hung, Inn-Wen Chong, Yu-Chen Tsai, Ying-Ming Tsai, Cheng-Hao Chuang, Hsiu-Mei Chang, Kuan-Li Wu, Yong-Chieh Chang, Yu-Kang Tu
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 4376, p 4376 (2021)
Journal of Clinical Medicine, Vol 10, Iss 4376, p 4376 (2021)
Various anaplastic lymphoma kinase inhibitors (ALKIs) have been approved for first-line use in treating anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). To date, no head-to-head comparison of these newer generation ALKI
Autor:
Inn-Wen Chong, Chin-Ling Chen, Chih-Jen Yang, Yong-Chieh Chang, Yu-Chen Tsai, Kung-Chao Chen, Hsiao-Ling Chen, Jui-Ying Lee, I-Hua Chen, Hsiu-Mei Chang, Kuan-Li Wu, Yu-Kang Tu, Cheng-Hao Chuang, Jen-Yu Hung
Publikováno v:
Cancers, Vol 13, Iss 1966, p 1966 (2021)
Cancers
Cancers
Simple Summary The prognosis of non-small cell lung cancer (NSCLC) is poor as more than half of the patients are diagnosed at an advanced stage. The outcomes have greatly improved in the recent two decades due to the introduction of target therapy. A
Autor:
Yung-Shun Juan, Vinson Wai-Shun Chan, Erica On-Ting Chan, Jeremy Yuen-Chun Teoh, Yu-Kang Tu, Hsiang-Ying Lee, Hsiu-Mei Chang, Hsiao-Ling Chen
Publikováno v:
Cancers
Volume 13
Issue 6
Cancers, Vol 13, Iss 1484, p 1484 (2021)
Volume 13
Issue 6
Cancers, Vol 13, Iss 1484, p 1484 (2021)
Simple Summary On the basis of the efficacy and tolerable safety profiles of immune checkpoints inhibitors (ICIs) in second-line metastatic urothelial carcinoma (mUC) patients, some emerging clinical trials focus on the first-line treatment. Thus, we